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Abstract
Background: Misfolding- and aggregation-prone proteins underlying Parkinson’s, Huntington’s and Machado-Joseph
diseases, namely a-synuclein, huntingtin, and ataxin-3 respectively, adopt numerous intracellular conformations during
pathogenesis, including globular intermediates and insoluble amyloid-like fibrils. Such conformational diversity has
complicated research into amyloid-associated intracellular dysfunction and neurodegeneration. To this end, recombinant
single-chain Fv antibodies (scFvs) are compelling molecular tools that can be selected against specific protein
conformations, and expressed inside cells as intrabodies, for investigative and therapeutic purposes.
Methodology/Principal Findings: Using atomic force microscopy (AFM) and live-cell fluorescence microscopy, we report
that a human scFv selected against the fibrillar form of a-synuclein targets isomorphic conformations of misfolded
polyglutamine proteins. When expressed in the cytoplasm of striatal cells, this conformation-specific intrabody co-localizes
with intracellular aggregates of misfolded ataxin-3 and a pathological fragment of huntingtin, and enhances the
aggregation propensity of both disease-linked polyglutamine proteins. Using this intrabody as a tool for modulating the
kinetics of amyloidogenesis, we show that escalating aggregate formation of a pathologic huntingtin fragment is not
cytoprotective in striatal cells, but rather heightens oxidative stress and cell death as detected by flow cytometry. Instead,
cellular protection is achieved by suppressing aggregation using a previously described intrabody that binds to the
amyloidogenic N-terminus of huntingtin. Analogous cytotoxic results are observed following conformational targeting of
normal or polyglutamine-expanded human ataxin-3, which partially aggregate through non-polyglutamine domains.
Conclusions/Significance: These findings validate that the rate of aggregation modulates polyglutamine-mediated
intracellular dysfunction, and caution that molecules designed to specifically hasten aggregation may be detrimental as
therapies for polyglutamine disorders. Moreover, our findings introduce a novel antibody-based tool that, as a consequence
of its general specificity for fibrillar conformations and its ability to function intracellularly, offers broad research potential
for a variety of human amyloid diseases.
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Introduction
Abnormal aggregation of polypeptides into amyloid-like fibrils is
associated with more than 20 known human disorders collectively
referred to as protein misfolding or conformational diseases [1].
Despite little shared sequence homology, amyloid-forming poly-
peptides show a common propensity to misfold into highly-
ordered polymers that are rich in fibrillar b-sheet structure.
Distinct amyloidogenic polypeptides are genetically implicated in
the progression of human neurodegenerative disorders, including
Alzheimer’s, Parkinson’s, polyglutamine, and prion diseases.
Human polyglutamine disorders such as Machado-Joseph disease
(MJD) and Huntington’s disease (HD) are caused by aberrant
codon expansion of CAG trinucleotide tracts within unrelated
genes encoding polyglutamine-domain proteins. In HD, expan-
sions beyond 37 consecutive glutamines within the huntingtin
protein confer a toxic gain-of-function phenotype related to its
intracellular aggregation in neurons [2]. Proteinaceous huntingtin
aggregates are diagnostic hallmarks of HD neuropathology and
coincide with neurological symptoms in humans [3] as well as in
transgenic models of the disease [4]. These intracellular aggregates
are composed chiefly of polyglutamine-containing amino-terminal
fragments of huntingtin that arise by proteolysis. Consequently,
the first exon of the human Huntingtin gene (Htt exon1)
containing an expanded CAG repeat is sufficient to induce HD-
like pathology, including intracellular aggregates and neurode-
generation, in transgenic mice models [5]. Likewise, neuronal
protein inclusions are clinically observed in MJD and arise
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repeat within the ataxin-3/MJD1/SCA3 locus [6].
Following destabilization of native protein folding by expanded
polyglutamine domains, the aggregation of mutant huntingtin or
ataxin-3 proceeds by nucleated growth polymerization into
protein fibrils that structurally resemble amyloid fibrils and react
with amyloid-specific histochemical dyes such as Congo Red or
thioflavin [7,8]. Analogous biophysical properties are observed for
b-amyloid and a-synuclein fibrils associated with Alzheimer’s and
Parkinson’s diseases, respectively [9]. Amyloid fibrils are thought
to be nucleated by monomers or globular oligomers of misfolded
protein [10]. In turn, fibrils may co-assemble into much larger
insoluble protein aggregates that are resistant to proteolysis. While
it is clear that protein misfolding can elicit cellular toxicity,
whether fibrillar protein aggregates are themselves toxic remains
the subject of intense debate. On one hand, a growing body of
evidence supports the ‘‘toxic soluble precursor’’ hypothesis in
which end-stage protein fibrils are increasingly considered benign
or even cytoprotective [11,12]. In support of this hypothesis, small
molecules that visibly stimulate inclusion-formation inside cells
appear to be beneficial [13]. However, contrasting studies have
achieved compelling cytoprotection by preventing fibrils and
aggregates from forming at all [14]. These competing hypotheses
are not mutually exclusive given the growing diversity in ‘‘on-
pathway’’ and ‘‘off-pathway’’ protein folding conformations
observed during amyloidogenesis [15].
Conventional antibodies raised against amyloid conformations
are known to cross-react with a wide variety of misfolded proteins,
thereby illustrating that diverse amyloidogenic proteins share
isomorphic features [16,17]. However, these conformation-specific
antibodies cannot be readily implemented inside living cells to
investigate the conformational toxicity of intracellular amyloido-
genic proteins such as huntingtin, a-synuclein, and ataxin-3 in situ.
In an alternative approach, recombinant single-chain Fv (scFv)
antibodies, which preserve the binding specificities of monoclonal
antibodies within the framework of a single small polypeptide, can
be selected in vitro and expressed intracellularly as ‘‘intrabodies’’
to probe huntingtin and a-synuclein in living cells [18,19]. By
encoding the antigen-binding site of an immunoglobulin within
the framework of a single nucleic acid coding sequence, scFvs are
amenable to genetic manipulation and expression as single genes
[20]. A recently developed technique for screening recombinant
scFv libraries against amyloidogenic protein morphologies has
identified several human conformation-specific scFvs against
oligomeric and fibrillar forms of a-synuclein [21,22]. Here, we
demonstrate that one such scFv antibody (scFv-6E) selected against
fibrillar a-synuclein targets isomorphic conformations of mutant
huntingtin and ataxin-3 and enhances the aggregation propensity
of these polyglutamine proteins in striatal cells. Using intrabodies
as kinetic tools for controlling amyloidogenesis, we show that
accelerating polyglutamine aggregation is not cytoprotective but
rather aggravates intracellular dysfunction and cell death. These
findings validate the importance of aggregation kinetics in
modulating the severity of polyglutamine-mediated neuronal
dysfunction.
Results
Fibril-specific scFv-6E intrabody co-localizes with
intracellular aggregates of misfolded httex1 and ataxin-3
Antibody scFv-6E was isolated by panning a synthetic human
scFv library against purified a-synuclein amyloid fibrils using a
combination of phage display and atomic force microscopy (AFM)
techniques [22]. By ELISA, scFv-6E exhibits conformation-specific
binding to fibrillar a-synuclein but not monomeric or oligomeric
species [22]. Drawing from evidence that fibrils of diverse
amyloidogenic proteins possess common structural epitopes [17],
we reasoned that scFv-6E may function as a conformational sensor
for other fibril-forming proteins such as polyglutamine proteins.
Therefore, we tested scFv-6E in cellular models of polyglutamine
disease using either human ataxin-3 (MJD1/SCA3) or a pathologic
huntingtin fragment encoded by the first exon of the Huntingtin
gene (Httex1), both of which form filamentous protein aggregates
dependent on polyglutamine tract length [7,8]. Through live-cell
microscopy, we confirmed that green fluorescent protein (GFP)-
tagged versions of these misfolding-prone proteins formed intracel-
lularaggregatesinimmortalized ratstriatal progenitorcells(ST14A)
with similar characteristics as widely documented in the literature
[23–26]. ST14A cells were chosen for this study because these
neuronal cells share features with medium-spiny neurons [27],
which are pre-disposed to HD neuropathology [28] and affected in
models of MJD [29]. We included in our transfections a nuclear
localization signal (NLS)-tagged monomeric red fluorescent protein
(NLS-mRFP) to label nuclei. Aside from this general purpose, NLS-
mRFP is a convenient marker for monitoring cellular stress in live
cells, as its mislocalization to the cytoplasm is indicative of nuclear
import collapse [30,31]. As illustrated in Figure 1A, GFP-labeled
mutant httex1, containing an expanded polyglutamine repeat (72Q)
associated with juvenile HD onset, rapidly formed cytoplasmic and
perinuclear aggregates in ST14A cells after 48 hours, whereas
httex1 containing a non-amyloidogenic polyglutamine repeat (25Q)
remained completely diffuse. Nuclear localization of httex1-GFP
was rarely observed in ST14A cells, as reported in other culture
modelsof HD [25,26,32]. The coalescence of misfoldedhttex1-72Q
species into intensely fluorescent aggregates resulted in the
disappearance of diffuse httex1-72Q-GFP species from the
surrounding cytoplasm (Fig. 1A, arrows), highlighting the rapid
precipitous nature of huntingtin aggregation [26]. Similarly, GFP-
tagged mutant ataxin-3, containing an expanded polyglutamine
tract (77Q) associated with MJD, predominately formed cytoplas-
mic aggregates in transfected ST14A cells over a similar time period
whereas non-expanded ataxin-3 (24Q) localized diffusely (Fig. 1B).
Unlike the case for httex1, ataxin-3 was not excluded from
nucleoplasm and therefore nuclear aggregates of GFP-ataxin-3-
77Q were occasionally present along with cytoplasmic aggregates.
Striking differences in aggregate size and frequency were clearly
evident between mutant ataxin-3 and httex1, as inclusions were
observed in ,70% of httex1-72Q transfected cells by 48 hours but
in only ,20% of ataxin-3-77Q transfected cells over a similar time
period, with ataxin-3-77Q inclusions appearing much smaller than
httex1 inclusions. These observations likely reflect the fact that
ataxin-3 was expressed in its native full-length form while httex1
represents an N-terminal fragment of the huntingtin protein that is
generated by proteolysis [33].
To determine whether scFv-6E antibody co-localizes with such
filamentous polyglutamine inclusions, we fused scFv-6E to the
amino-terminus of enhanced monomeric red fluorescent protein
(mRFP Q66T) to create traceable scFv-6E ‘‘fluorobodies’’ that can
be directly visualized in live cells through fluorescence microscopy
[34]. To minimize folding interference, a flexible (Gly4Ser)4
peptide linker was cloned between scFv-6E and mRFP to ensure
that each moiety folds independently and produces a functional
fluorescent scFv fusion, as suggested in other studies [35–37].
When co-expressed with fluorescently-labeled httex1 or ataxin-3
possessing disease-related polyglutamine repeats, we observed that
scFv-6E fluorobodies formed intracellular puncta that co-localized
with aggregates of mutant httex1-72Q and ataxin-3-77Q (Fig. 2A,
B). In some cells, scFv-6E fluorobodies encircled polyglutamine
Fibril-Specific Intrabody
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reminiscent of the recruitment of specific binding partners onto the
surface of protein aggregates [38]. In contrast, scFv-6E fluorobody
adopted a diffuse localization pattern in the presence of non-
amyloidogenic httex1-25Q-GFP, and showed little specific overlap
with soluble httex1-25Q species as indicated by clear differences in
the nuclear versus cytoplasmic localization of these two reporters
(Fig. 2A). Importantly, co-localization of scFv-6E fluorobody with
httex1-72Q inclusions could be suppressed by blocking aggrega-
tion using a second intrabody, scFv-C4, that binds within the first
17 amino-terminal residues of huntingtin [19] (Fig. 2A). In the
presence of scFv-C4, fibril-specific scFv-6E fluorobody shifted
from a punctate localization to a diffuse pattern (Fig. 2A),
suggesting that scFv-C4 intrabody blocked the formation of
misfolded httex1 epitopes normally recognized by scFv-6E. As an
additional control, GFP-labeled scFv-C4 fluorobody completely
inhibited httex1-72Q aggregation in live ST14A cells and co-
localized perfectly with non-aggregated httex1-72Q in the
cytoplasm (Fig. S1), demonstrating that our fluorobody design
generates functional fluorescently-tagged intrabodies. Moreover, a
nonspecific control fluorobody (B8-GFP) selected against botuli-
num neurotoxin light chain protease [39] failed to co-localize with
aggregates of fluorescently-labeled httex1-72Q in ST14A cells
(Fig. 2C), suggesting that the observed co-localization of scFv-6E
fluorobody with polyglutamine inclusions is direct. In total, these
co-localization experiments support our hypothesis that scFv-6E is
a conformation-specific antibody fragment capable of distinguish-
ing disease-related amyloid proteins with filamentous structure
inside cells.
6E scFv binds httex1 amyloid fibrils and enhances
fibrillogenesis in solution
To confirm that scFv-6E binds fibrillar huntingtin species
directly, we employed an AFM-based in vitro technique for
measuring antibody affinity to specific protein morphologies [40].
Following standard protocols for generating httex1 fibrils contain-
ing an expanded polyglutamine tract (51Q) typical of adult HD
onset [8], mutant httex1 fibrils were deposited onto freshly cleaved
mica for surface height analyses by AFM. By measuring changes in
the surface height of fibrils before and after incubation with scFv
antibodies, we were able to detect that purified 6E scFv, but not a
control scFv against phosphorylase B (aPLB), bound specifically to
fibrillar httex1-51Q (Table 1). Binding of scFv-6E to httex1-51Q
fibrils increased the average surface height of these fibrils by nearly
2-fold compared to identical fibrils incubated with a control scFv
(aPLB) or in buffer alone (Table 1). Similar increases in particle
height were observed when mature a-synuclein fibrils, but not
purified oligomeric or monomeric a-synuclein species, were
incubated with scFv-6E in vitro [40]. These results support prior
conclusions that misfolded huntingtin and a-synuclein exhibit
common structural amyloid epitopes, as first revealed by others
using conformation-specific conventional antibodies [16,41]. To
confirm our AFM findings and test whether scFv-6E may also be
specific for soluble conformers of mutant protein, we next assayed
for direct antibody-antigen interactions in ST14A cells using
subcellular re-localization assays. A potent nuclear localization
sequence (NLS) derived from SV40 Large T antigen was fused to
scFv-6E to target intrabody/antigen complexes into nuclei. By
transient transfection, we observed that scFv-6E-NLS failed to
recruit soluble species of either mutant httex1-72Q-GFP or GFP-
ataxin-3-77Q into nuclei (Fig. 3A, B), contrary to a control NLS-
tagged intrabody (scFv-C4-NLS, Fig. 3A) shown previously to bind
and sequester soluble httex1 species into nuclei [19]. Instead, we
observed that scFv-6E-NLS intrabody sequestered tiny cytoplas-
mic aggregates of both GFP-ataxin-3-77Q and httex1-72Q-GFP
into nuclei (Fig. 3A, B, insets), although larger aggregates often
remained perinuclear likely due to steric constraints at nuclear
pores. In total, these findings validate our fibril specificity data in
Table 1 and demonstrate that scFv-6E is specific for a
conformational epitope typical of insoluble amyloid-like aggregates
but not soluble species of mutant protein.
Figure 1. Localization of GFP-tagged httex1 and full-length
ataxin-3 in live ST14A striatal progenitor cells. ST14A cells were
transiently transfected with httex1-GFP or GFP-ataxin-3 reporters
containing normal or disease-associated polyglutamine tract lengths,
and NLS-mRFP to label nuclei. Representative live-cell images were
captured 48 hours post-transfection as described in Materials and
Methods. (A) GFP-tagged httex1-25Q localizes diffusely in the
cytoplasm while mutant httex1-72Q precipitously forms large aggre-
gates (arrows) in the cytoplasm, which often appear juxtaposed to
nuclei. (B) GFP-tagged ataxin-3-24Q localizes diffusely within ST14A
cells while mutant ataxin-3-77Q forms small aggregates (arrows)
predominately in the cytoplasm. Scale bars, 25 mm.
doi:10.1371/journal.pone.0005727.g001
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scFv-6E altered mutant httex1 aggregation kinetics in solution.
Cell-free, de novo aggregation studies of purified httex1-51Q
protein were conducted in the absence or presence of scFv-6E, and
fibril-formation was monitored spectrophotometrically using
Thioflavine S (ThS), an amyloid-specific dye that undergoes a
spectral shift upon binding fibrils [1]. Approximately 24 hours
after initiating aggregation, httex1-51Q samples incubated with
scFv-6E exhibited 2765% higher levels of ThS fluorescence on
average than buffer-treated control samples, thus indicating
Figure 2. scFv-6E fluorobodies co-localize with intracellular aggregates of mutant httex1 and ataxin-3 in live cells. ST14A cells were
transiently transfected with the indicated GFP- and mRFP-tagged reporters, and representative live-cell images were captured 48 hours post-
transfection as described in Materials and Methods. (A) mRFP-tagged scFv-6E fluorobody co-localizes as intracellular puncta with cytoplasmic
aggregates of GFP-tagged httex1-72Q (arrows), occasionally in a ring-like pattern (inset i). Transfection with unlabeled scFv-C4 efficiently suppresses
co-localization of scFv-6E fluorobody with inclusions by inhibiting the aggregation of httex1-72Q-GFP. In the absence of httex1 inclusions, scFv-6E
fluorobody exhibits a diffuse localization pattern. (B) mRFP-tagged scFv-6E fluorobody co-localizes with cytoplasmic and nuclear aggregates of GFP-
tagged ataxin-3-77Q (arrows). (C) GFP-labeled control intrabody (B8) selected against botulinum neurotoxin light chain protease fails to co-localize
with mutant httex1-72Q-mRFP inclusions. Scale bars, 25 mm.
doi:10.1371/journal.pone.0005727.g002
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fluorescence were observed at earlier time points during httex1-
51Q oligomerization (Fig. 4A) or after 24 hour incubation with a
control scFv against phosphorylase B (Fig. 4A). AFM imaging of
these samples confirmed that httex1-51Q fibrils were more
abundant following incubation with fibril-specific scFv-6E
(Fig. 4B). Importantly, httex1-51Q fibrils appeared structurally
identical between samples incubated with or without scFv-6E
(Fig. 4B) and displayed branched morphologies characteristic of
mutant huntingtin [42]. To validate the binding specificity of scFv-
6E, protein aliquots of mutant httex1 from pre-cleared control
reactions were applied onto nitrocellulose at specific time points
during fibrillogenesis and probed against scFv-6E by dot-blot
analysis. These experiments confirmed that scFv-6E binds httex1
at time points when fibrils predominate (24, 144 hours) but not at
earlier time points (0, 1, 6 hours) when monomers and oligomers
prevail (Table 2). In total, these in vitro findings imply that scFv-
6E likely enhances the kinetic aggregation of httex1-51Q by
binding and stabilizing nascent fibrils, thereby reducing the
thermodynamic lag-time of fibrillogenesis.
Figure 3. NLS-fused scFv-6E intrabody retargets polyglutamine aggregates but not soluble polyglutamine species in situ. Antibody-
antigen interactions were probed in ST14A cells using NLS-fused scFv-6E to sequester both intrabody and bound antigen into nuclei. NLS-mRFP
fluorescence marks nuclei. Representative live-cell images were captured as described in Materials and Methods. (A) NLS-fused scFv-6E sequesters
small cytoplasmic aggregates of GFP-labeled httex1-72Q (inset, arrow) but not soluble species into nuclei. In contrast, a control NLS-fused intrabody
(scFv-C4-NLS) completely recruits soluble httex1-Q72-GFP species into nuclei from the cytoplasm. (B) NLS-fused scFv-6E completely sequesters
aggregates of GFP-labeled ataxin-3-77Q (inset, arrow) but not soluble species into nuclei. Scale bars, 25 mm.
doi:10.1371/journal.pone.0005727.g003
Table 1. Mean particle height of httex1-51Q fibrils incubated
with/without scFvs.
Treatment n Mean height (nm)
a SD (nm) p-value
buffer 52 2.51 60.53 NA
6E scFv 53 4.25 60.90 ,0.0001
aPLB scFv 48 2.47 60.56 0.7438
aSurface height measurements were obtained by cross-sectional analysis of
httex1-51Q fibrils deposited on mica and incubated with or without scFvs as
described in Materials and Methods. Absolute maximum z-heights were
averaged from 10–20 cross-sections per fibril using line profiles drawn
perpendicular to the fibril axis. Fibrils (n) were analyzed in three separate
sections of mica per sample. P-values represent statistical significance from
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of mutant httex1
We next tested if scFv-6E enhanced the aggregation of mutant
httex1 when expressed as an intrabody inside neuronal cells. To
this end, unlabeled scFv-6E was cloned downstream of a strong
viral promoter and co-expressed with mutant httex1-72Q-GFP in
ST14A cells. At 48 hours post-transfection, we observed 3362.2%
more GFP-labeled httex1-72Q aggregates in the cytoplasm of cells
co-transfected with scFv-6E intrabody than with vector alone
(Fig. 5A, B), in good agreement with our in vitro findings (Fig. 4).
Due to the stochastic nature of httex1 aggregation, aggregate
frequency increased both population-wide and per cell following
expression of scFv-6E, with qualitatively more cells containing
multiple cytoplasmic aggregates (Fig. 5A). Interestingly, NLS-
mRFP was generally mislocalized to the cytoplasm of aggregate-
laden cells (Fig. 5A, asterisks), indicating a collapse in nuclear
import, which is a hallmark of cellular stress [30,31]. By exploiting
the fact that the fluorescence intensity of httex1-72Q-GFP
increases during aggregation (Fig. 1A), we were able to confirm
by flow cytometry that scFv-6E augments httex1-72Q aggregation
in situ. Cells with intense httex1-72Q-GFP fluorescence (10
3–10
4
arbitrary fluorescence units, AFU) increased in frequency
following expression of scFv-6E intrabody compared to vector
alone (Fig. 5C, arrows), indicating a proliferation in GFP-labeled
mutant httex1 inclusions. Importantly, no significant differences in
GFP fluorescence were observed at lower peak intensities (10
1–10
3
Figure 4. scFv-6E enhances the fibrillar aggregation of mutant httex1 in solution. (A) Fluorescence intensity of Thioflavine S-stained
httex1-51Q fibrils formed in the presence or absence of scFv antibodies. Purified httex1-51Q, scFv-6E, and scFv-aPLB proteins were prepared as
described in Materials and Methods. Samples were analyzed 0, 3, and 24 hours after initiating aggregation. Each bar represents mean Thioflavine S
fluorescence (arbitrary fluorescence units, AFU) from reactions performed in triplicate. Statistical significance (** p,0.01) was determined by ANOVA.
(B) Representative AFM images of httex1-51Q aggregation reactions conducted in the absence or presence of scFv-6E. AFM scan size, 5 mm65 mm.
doi:10.1371/journal.pone.0005727.g004
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differences could account for this result. Taken together, we
conclude that scFv-6E enhances mutant httex1 aggregation in situ
as well as in solution. These findings starkly contrasted with
experiments conducted in parallel using anti-huntingtin scFv-C4
intrabody, which strikingly blocked mutant httex1 aggregation in
ST14A striatal cells (Fig. 5A, B), consistent with published
observations in other models [19,43].
Recombinant scFv antibodies are generally destabilized when
expressed as cytoplasmic intrabodies due to the redox-inhibition of
intrachain disulfide bonds that normally play a role in antibody
folding [44]. We recognized this fact could directly influence the
aggregation kinetics of huntingtin, since studies have shown that
destabilized proteins may function as non-specific modifiers of
polyglutamine misfolding by sequestering chaperones and eliciting
global protein folding stress [45]. To test if the observed effects of
scFv-6E intrabody on httex1 aggregation kinetics might be
indirect, we repeated our intracellular studies using a nonspecific
scFv (ML3.9) against the extracellular domain of the cell surface
tumor receptor c-erbB-2 [46]. When expressed in cell cytoplasm as
a GFP-labeled fluorobody, scFv-ML3.9 exhibited striking insolu-
bility as indicated by the formation of intracellular aggregates, in
contrast to scFv-6E and -C4 fluorobodies, which generally
exhibited diffuse cytoplasmic localization patterns consistent with
soluble proteins (Fig. 6A,B). Despite such intrinsic instability in cell
cytoplasm, scFv-ML3.9 intrabody failed to significantly enhance
the intracellular aggregation of httex-72Q-GFP in ST14A cells as
judged by our scoring assay (Fig. 5B), consistent with prior
observations in other cell types [19]. By analogy, we conclude that
the stimulatory effects of scFv-6E intrabody on httex1 aggregation
are direct, and cannot be simply explained by folding stress related
to intrabody expression. This conclusion is further supported by
the fact that scFv-6E localizes and generally fractionates as a
soluble intracellular protein (Fig. 6A, B), even when expressed at
elevated levels to increase the potential for folding stress (Fig. 6C),
as well as the fact that scFv-6E directly enhances fibrillar
aggregation of mutant httex1 in cell-free experiments (Fig. 4).
scFv-6E and -C4 intrabodies differentially affect httex1-
dependent toxicity in situ
A growing body of evidence has suggested that protein
inclusions large enough to be visible by light microscopy might
be irrelevant to misfolded-protein pathology or even cytoprotec-
tive [47]. The ability of scFv-6E to target intracellular amyloids
offered a unique opportunity to test these models in situ. Using
huntingtin as a paradigm, we compared the viability of ST14A
cells expressing GFP-labeled mutant httex1 in the presence or
absence intrabody. Approximately 48 hours post-transfection,
ST14A cells were incubated with propidium iodide (PI), a
membrane-impermeant dye that labels necrotic cell nuclei
following membrane damage, and PI fluorescence was co-sorted
against GFP-labeled httex1 fluorescence by flow cytometry. As
shown in Figure 7A–C, expression of mutant httex1-72Q-GFP
alone resulted in greater PI staining and toxicity than non-
amyloidogenic httex1-25Q-GFP. Accelerating the aggregation of
mutant httex1 with scFv-6E intrabody elicited a further increase in
PI-staining (Fig. 7B, C), particularly among cells exhibiting large
or numerous inclusions as indicated by a prominent forward shift
in GFP fluorescence intensity (10
3–10
4 AFU, Fig. 7A, see arrows)
within these cells. This small but statistically significant (p,0.001)
increase in cell death is consistent with the modest increase in
httex1-72Q aggregate load (3362.2%) elicited by scFv-6E (Fig. 5A,
B). In contrast, blocking httex1-72Q-GFP aggregation with scFv-
C4 intrabody completely abolished polyglutamine-dependent
toxicity (Fig. 7A, B). More importantly, scFv-C4 intrabody also
suppressed mutant httex1 aggregation and toxicity in the presence
of scFv-6E intrabody (Fig. 7C, 2A). These results confirm that
scFv-C4 functions upstream of scFv-6E with regard to mutant
httex1 aggregation kinetics. As an additional control for specificity,
cells expressing intrabody in the presence of GFP alone showed
virtually no toxicity (Fig. 7B).
To verify our findings, we repeated the above experiments using
YOPRO-1, a DNA-intercalating dye that labels apoptotic as well
as necrotic cells [48]. Because YOPRO-1 emits fluorescence in the
green spectra, we cloned and expressed mRFP-labeled httex1
reporters that emit red fluorescence. By flow cytometry, we
observed a pattern of YOPRO-1 staining that exactly paralleled
our PI results, as the cellular toxicity of mutant httex1-72Q
increased in an aggregation-specific manner with scFv-6E intra-
body but was completely suppressed upon blocking aggregation
with scFv-C4 intrabody (Fig. 7C). Thus, our findings illustrate that
escalating mutant httex1 aggregate formation is not cytoprotective,
but rather enhances polyglutamine-dependent toxicity. However,
we should stress that total cell death remained relatively low
(,15%) among cells expressing mutant httex1-72Q with or
without scFv-6E intrabody (Fig. 7B), and thus the vast majority
of cells bearing httex1 aggregates were overwhelmingly viable
within this 48 hr period. Taken together, we conclude that the
aggregation of mutant httex1 is not instantly toxic to ST14A
striatal-derived cells but rather gradually compromises viability
over time.
scFv-6E intrabody augments httex1-mediated oxidative
stress
Recent studies have highlighted a role for huntingtin in eliciting
mitochondrial dysfunction and oxidative stress [49,50]. We
observed by live-cell fluorescence microscopy that cells with
mutant httex1 inclusions tended to exhibit defects in NLS-mRFP
nuclear import (Fig. 5A, see asterisks), which can be a consequence
of oxidative stress [30,31]. To directly test if the aggregation of
Table 2. Relative staining intensity of scFv-6E probed by dot-blot against mutant httex1 at specific time points during
fibrillogenesis
a.
Time point 0 1 hour 6 hours 24 hours 144 hours
scFv-6E staining intensity 1.00 1.1060.28 1.2860.14 2.2260.20 3.3260.18
aStaining intensities were determined by dot-blot analysis of httex1-53Q using scFv-6E as a primary antibody. Briefly, purified GST-httex1-53Q protein was
ultracentrifuged to remove preformed particles and digested to initiate httex1-53Q aggregation as described in Materials and Methods. Aliquots of httex1-53Q were
deposited onto nitrocellulose 0, 1, 6, 24, and 144 hours after initiating aggregation and probed against scFv-6E by dot-blot. Results from duplicate experiments were
averaged and normalized to time 0 values. Higher scFv-6E staining is observed at later time points when httex1-53Q is predominately fibrillar but not earlier time
points when monomers and oligomers prevail.
doi:10.1371/journal.pone.0005727.t002
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transiently transfected ST14A cells with dihydroethidium (DHE,
also known as hydroethidine), a fluorescent redox indicator that is
readily cell-permeant. As a consequence of elevated oxidative
stress and reduced mitochondrial membrane potential, DHE
becomes enzymatically oxidized, in part, to ethidium bromide,
which binds DNA and emits a bright red fluorescence [51]. Using
flow cytometry, we quantified the production of ethidium bromide
in DHE-stained ST14A cells expressing GFP-tagged httex1 and
either intrabody or vector. As shown in Figure 7C, oxidation of
DHE increased concomitantly with httex1-72Q aggregation in the
presence of fibril-specific scFv-6E intrabody but was completely
suppressed by blocking aggregation with scFv-C4 intrabody.
Fluorescence microscopy confirmed that ST14A cells possessing
httex1-72Q aggregates showed increased ethidium bromide
fluorescence after loading with DHE, consistent with prior studies
Figure 5. scFv-6E intrabody enhances mutant httex1 aggregation in ST14A cells. (A) Representative live-cell images depicting the
localization patterns of httex1-72Q-GFP and NLS-mRFP in the absence or presence of intrabodies. scFv-6E intrabody increases the frequency of
cytoplasmic httex1-72Q aggregates while scFv-C4 intrabody blocks aggregate formation in ST14A cells. Asterisks denote cells where NLS-mRFP
nuclear import is impaired, indicating cell stress. Scale bars, 25 mm. (B) Relative aggregation propensity of httex1-72Q in the absence or presence of
intrabodies. Aggregates of httex1-72Q-GFP were scored as described in Materials and Methods. Statistical significance (*** p,0.0001) was
determined by ANOVA (n=4). (C) FACS histogram of httex1-72Q-GFP fluorescence intensity (arbitrary fluorescence units, AFU) plotted as a function
of cell number. ST14A cells co-expressing httex1-72Q-GFP and either scFv-6E (black) or empty vector (gray) were sorted by fluorescence intensity as
described in Materials and Methods. Representative data from triplicate experiments were superimposed.
doi:10.1371/journal.pone.0005727.g005
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aggregation of httex1 is cytotoxic to ST14A striatal-derived cells
due, in part, to increased oxidative stress.
scFv-6E intrabody boosts human ataxin-3 aggregation
and toxicity
To extend our analysis and confirm that scFv-6E accelerates
protein amyloidogenesis, we tested scFv-6E against full-length
human ataxin-3, which possesses a unique propensity to aggregate
through non-polyglutamine domains [53]. Thus, unlike the case
for huntingtin, polyglutamine expansion is not required for
nucleating ataxin-3 fibrillogenesis in solution [53]. Rather, self-
interactions mediated by the amino-terminal Josephin domain of
ataxin-3 are thought to initiate fibrillogenesis [7,54]. However, in
vitro studies demonstrate that ataxin-3 fibrils formed in the
absence of long polyglutamine tracts are less stable than those
formed by expanded ataxin-3; thus, expanded polyglutamine plays
a modulating role in the thermodynamics and kinetics of ataxin-3
fibrillogenesis [7,53]. Given that scFv-6E antibody binds fibrils and
appears to reduce the lag-time of huntingtin fibrillogenesis (Figs. 4,
5), we hypothesized that scFv-6E may also accelerate the
Figure 6. Relative intrabody solubility. (A) Live images of ST14A cells co-transfected with GFP-tagged fluorobodies and NLS-mRFP, a nuclear
marker. Cells were imaged 48 hours post-transfection as described in Materials and Methods. scFv-6E fluorobody predominately localizes as a diffuse
soluble protein similar to anti-huntingtin scFv-C4 fluorobody. scFv-ML3.9 fluorobody localizes almost entirely as inclusions. Note NLS-mRFP nuclear
import is perturbed in the presence of scFv-ML3.9 inclusions (asterisks), indicating cell stress. (B) Biochemical fractionation of HA-tagged fluorobodies
from ST14A cells. Detergent-soluble and -insoluble cell lysates were prepared as described in Materials and Methods. (C) Biochemical fraction of HA-
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transfected ST14A cells with GFP-labeled versions of non-
expanded (24Q) or polyglutamine-deleted (DQ) ataxin-3, and
tested for accelerated ataxin-3 inclusion formation in the presence
of scFv-6E intrabody by live-cell fluorescence microscopy. As
shown in Figure 8A, non-expanded GFP-ataxin-3 (24Q) exhibited
a mostly diffuse and non-aggregated localization pattern alone but
formed multiple intracellular aggregates in the presence of scFv-6E
intrabody after 48 hours. Similar results were observed with GFP-
labeled ataxin-3 deleted of polyglutamine (DQ) (Fig. 8A). In
contrast, scFv-6E intrabody failed to stimulate the visible
aggregation of non-expanded httex1 (25Q) (Fig. 8A), which is
not known to form fibrils naturally [42]. Together, these results
demonstrate that fibril-specific scFv-6E kinetically escalates
intracellular amyloidogenesis through a conformation-specific
and thermodynamic mechanism that is independent of protein
sequence.
We next investigated the relationship between ataxin-3
aggregation and toxicity using a combination of microscopy and
flow cytometry. GFP-labeled aggregates of pathologic (77Q) or
non-disease-associated (24Q) ataxin-3 were scored in ST14A cells
in the presence or absence of intrabody, and cellular toxicity and
oxidative stress were measured using PI and DHE vital dyes,
respectively. These analyses revealed that ataxin-3 toxicity
increased concomitantly with aggregation propensity (Fig. 8B,
C), even when ataxin-3 contained a non-disease-associated
polyglutamine repeat (24Q). Thus, non-pathologic ataxin-3 could
be transformed into a toxic protein by stabilizing and accelerating
its intrinsic ability to aggregate using scFv-6E. Compared to
parallel data collected against mutant httex1 (Fig. 5B, 7C), these
Figure 7. scFv-6E and -C4 intrabodies differentially affect mutant httex1-mediated toxicity and oxidative stress in situ. (A) Two-color
FACS dot-plots from representative experiments in which ST14A cells were transiently transfected with the indicated reporters, stained with
propidium iodide (PI) to label dead cells, and co-sorted for GFP and PI fluorescence intensity. A total of 30,000 cells were plotted on a logarithmic
scale of arbitrary fluorescence intensity. Grid lines were positioned after calibrating the flow cytometer as described in Materials and Methods. Lower
right quadrants demarcate viable transfected cells (GFP
+ PI
2). Upper right quadrants signify PI-labeled dead or dying transfected cells (GFP
+ PI
+). Note
that scFv-6E intrabody shifts httex1-72Q-GFP fluorescence to a higher intensity among PI-labeled cells (arrows), indicating that these cells died with
intensely fluorescent aggregates. (B) Percentage of cell death observed by two-color FACS analysis with PI. Cell death was calculated by dividing the
number of PI-stained transfected cells (GFP
+ PI





upper and lower right quadrants in A). Statistical significance from httex1-72Q-GFP alone (** p,0.001, *** p,0.0001) was determined by ANOVA
(n=3). (C) Relative cell staining of PI, YOPRO-1, and dihydroethidium (DHE) dyes as detected by two-color FACS. ST14A cells were transiently
transfected with the indicated GFP- or mRFP-labeled httex1 reporters (with or without scFv-6E and scFv-C4 intrabodies) and incubated with PI,
YOPRO-1, or DHE as described in Materials and Methods. Cell staining percentages were calculated by dividing the number of dye-stained transfected
cells by the total number of transfected cells, and data were normalized to non-expanded httex1-25Q alone. Statistical significance from expanded
httex1-72Q alone (* p,0.01, ** p,0.001, *** p,0.0001) was determined by ANOVA (n=3).
doi:10.1371/journal.pone.0005727.g007
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due to kinetic differences in the amyloidogenic properties of these
two polyglutamine proteins. In the absence of intrabody, we noted
that ataxin-3 formed fewer aggregates than mutant httex1 in
ST14A cells, suggesting that the amyloidogenesis of full-length
ataxin-3 occurs with a longer lag-phase inside cells, and thus a
greater window of opportunity may exist for scFv-6E intrabody to
influence aggregation. Interestingly, oxidative stress was not
significantly associated with ataxin-3 aggregation and toxicity as
measured using DHE (Fig. 8C), unlike the case for mutant httex1
(Fig. 7C). These findings validate that the downstream toxic effects
of amyloidogenesis are highly dependent on protein sequence, and
support the notion that sequences other than the polyglutamine
domains of httex1 and ataxin-3 influence the etiology of cellular
dysfunction through distinct protein-interaction networks [55].
Thus, conformation-specific intrabodies such as scFv-6E offer
Figure 8. scFv-6E intrabody enhances aggregation and toxicity of both normal and disease-associated ataxin-3. (A) Live-cell images
depicting GFP localization patterns of non-disease-associated ataxin3-24Q, ataxin3-DQ (lacking a polyglutamine tract), or httex1-25Q in the absence
or presence of scFv-6E intrabody. scFv-6E intrabody stimulates the intracellular aggregation of ataxin-3 (arrows) but not httex1-25Q. Scale bars,
25 mm. (B) Relative aggregation propensity of normal (24Q) or disease-linked (77Q) ataxin-3 in the absence or presence of scFv-6E intrabody. GFP-
tagged ataxin-3 aggregates were scored in ST14A as described in Materials and Methods. Statistical significance (** p,0.001, *** p,0.0001) was
determined by ANOVA (n=3). (C) Relative cell staining of propidium iodide (PI) and dihydroethidium (DHE) vital dyes as detected by two-color FACS.
ST14A cells were transiently transfected with normal (24Q) or disease-linked (77Q) GFP-ataxin-3 and either scFv-6E intrabody or empty vector. Cell
staining percentages were calculated as described in Materials and Methods, and data were normalized to GFP-ataxin-3-24Q alone. Statistical
significance (* p,0.01, *** p,0.0001) from GFP-ataxin-3-24Q was determined by ANOVA (n=3).
doi:10.1371/journal.pone.0005727.g008
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consequence of protein misfolding and aggregation across a wide-
spectrum of human amyloid disorders.
Discussion
Intracellular protein aggregation is linked to the onset and
progression of a variety of human amyloid disorders, although
whether or not visible protein inclusions are innately toxic remains
a matter of contention. Accumulating evidence from HD and
other amyloidogenic disease models has led to the ‘‘toxic soluble
precursor’’ hypothesis, which proposes that toxic intermediates
formed during amyloidogenesis might be ‘‘detoxified’’ through
their polymerization into insoluble amyloid-like fibrils [11]. As a
result, visible protein aggregates are increasingly thought to fulfill a
protective cellular response. This model is indirectly supported by
cytoprotective evidence obtained using small molecules that
promote the intracellular aggregation of huntingtin as well as a-
synuclein [13] via an undetermined mechanism. In this study, we
demonstrate a direct enhancement of huntingtin and ataxin-3
aggregation using a fibril-specific scFv antibody (scFv-6E) that
discriminates intracellular aggregates in situ. This conformation-
specific scFv recognizes a fibrillar epitope also characteristic of a-
synuclein, which scFv-6E was originally selected against [22].
Since little sequence homology exists between a-synuclein,
huntingtin, and ataxin-3, we speculate that scFv-6E recognizes a
structural epitope common to amyloid morphologies such as the
cross b-sheet motif. As a result, conformation-specific scFv
antibodies such as 6E have broad research potential for a variety
of human amyloid disorders. Using scFv-6E as a kinetic tool for
enhancing amyloidogenesis, we show that targeting aggregation of
mutant huntingtin in striatal cells is not protective, but rather
promotes oxidative stress and cell death. These results are
consistent with prior findings demonstrating a role for misfolded
huntingtin in eliciting mitochondrial dysfunction and oxidative
stress [49,50]. A similar inter-relationship between aggregation
and toxicity is observed for both normal and disease-associated
ataxin-3, although through a mechanism apparently distinct from
oxidative stress. In total, these results lend caution to the pursuit of
therapeutic strategies aimed at enhancing protein aggregation as
treatments for HD and related polyglutamine disorders [47].
Interestingly, preliminary cellular studies using scFv-6E intrabody
to target fibrillar a-synuclein suggest that a different therapeutic
strategy may apply for synucleinopathies compared to polygluta-
mine diseases (S. Lynch, unpublished data).
The data presented in this report are consistent with numerous
studies supporting an aggregation model for polyglutamine
pathogenesis. Elevated toxicity is reported in several HD models
after stimulating aggregation through such means as chaperone
depletion [56,57], dopamine exposure [58], inhibiting autophagy
[59], expressing anti-polyglutamine recombinant intrabodies [60],
depleting normal cellular prion protein [61], or overexpressing
specific huntingtin-interacting proteins such as intersectin or
normal repeat-length huntingtin fragments [62,63]. Our findings
argue against a protective role of protein inclusions in sequestering
and detoxifying soluble misfolded intermediates, since accelerating
the rate of fibrillogenesis would likely decrease the concentration
of such ‘‘on-pathway’’ intermediate conformers. Instead, we
observed that cellular toxicity ultimately correlated with the
formation of visible polyglutamine aggregates. Consistent with this
observation, blocking aggregate-formation using an intrabody
(scFv-C4) that binds within the first 17 amino acid residues of
huntingtin potently suppressed httex1-mediated toxicity, analo-
gous to its protective role in other HD models [19,43,64]. We
demonstrated previously that scFv-C4 intrabody binds preferen-
tially to non-aggregated NH2-terminal huntingtin fragments and
disrupts aggregation de novo, thereby eliciting greater turnover of
httex1 fragments in situ [65]. Recent data now show that the
epitope of scFv-C4 (aa 1–17 of huntingtin) is a membrane-binding
amphipathic helix sufficient for targeting mitochondrial and ER
membranes and necessary for triggering the aggregation of
expanded huntingtin fragments [49,66,67]. These properties
may explain how scFv-C4 intrabody mechanistically reduces
aggregation, oxidative stress, and toxicity, namely by shielding this
amyloidogenic huntingtin domain.
Several important factors likely explain why our results disagree
with the findings of Bodner et al [13]. This group identified a
cytoprotective compound called B2 that indiscriminately boosts
the size of httex1 and a-synuclein inclusions, perhaps through an
inhibitory effect on SIRT2 histone deacetylase [68]. Since
compound B2 does not interact directly with huntingtin or a-
synuclein, its cytoprotective effects may be pleiotropic and
unrelated to inclusion body formation, analogous to the protective
role of heat-shock protein Hsp27, which shows indirect activity in
modulating huntingtin aggregation but a more fundamental role
in antagonizing caspase activation and apoptosis in HD models
[69]. In contrast, our fibril-specific scFv-6E antibody directly
stimulates httex1 aggregation in solution and co-localizes with
ataxin-3 and httex1 inclusions in situ, suggesting that scFv-6E
interacts directly with amyloidogenic polypeptides through a
conformational epitope produced during fibrillogenesis. It is
possible that scFv-6E intrabody, by increasing aggregate load,
might expand the protein-recruiting surface area of intracellular
aggregates, which in turn could enhance toxicity by sequestering
more aggregate-interacting proteins away from their native
functions. In this context, compound B2 appears to decrease the
net surface area of aggregates by amassing multiple small
aggregates into a single large inclusion [13]. This apparent
relationship between aggregate size and ‘‘toxic surface area’’
deserves further investigation, especially with regard to intracel-
lular amyloidogenic proteins in compound aggregated states such
as inclusion bodies and aggresomes. Alternatively, we cannot
exclude the possibility that scFv-6E may stabilize a recently
described oligomeric species having fibrillar features [16],
although the existence of such oligomers has yet to be correlated
with cytopathology. On this subject, it is noteworthy that the
fibrillogenesis of ataxin-3 is initiated by a monomeric nucleus and
grows by monomer addition rather than through oligomers in
solution [7], and a similar mechanism may hold true for mutant
httex1 as well [70–72].
Paradoxically, viable cells containing intracellular aggregates
significantly outnumbered those that died with aggregates in our
cytotoxicity experiments, demonstrating that aggregates per se are
not instantly toxic to ST14A striatal-derived cells. This observation
is consistent with previous reports demonstrating a penchant for
inclusion bodies to be protective [12,73], a fact which has called
into question how visible protein aggregation can be associated
with neuropathological abnormalities even though aggregates
themselves are not universally predictive of neurodegeneration
[3,74]. Using intrabodies to alter the kinetics of amyloidogenesis,
our data illustrates that the overall speed of aggregate formation
bears more relevance to the severity of intracellular dysfunction
than whether or not inclusions are present at any given time point.
Indeed, time-lapse microscopy in a PC12 cell model of HD has
revealed that aggregation tends to occur rapidly in cells that die
with inclusions and much slower in cells that survive with
inclusions [73]. We conclude that the rate of aggregation likely
influences the magnitude of cellular dysfunction elicited by
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Hence, escalating the formation of httex1 aggregates with a fibril-
specific intrabody heightens oxidative stress and results in greater
toxicity in ST14A striatal cells. In contrast, suppressing aggrega-
tion with an intrabody that shields the amyloidogenic N-terminus
of mutant huntingtin in fact reduces oxidative stress and toxicity in
these cells. Importantly, oxidative stress complements several
prevailing models of HD pathogenesis, including excitoxicity,
mitochondrial dysfunction, and inflammation, as evidenced by the
ability of the mitochondrial poison 3-nitropropionic acid (3-NP) to
mimic striatum-specific HD-like motor defects [75]. Conversely,
ataxin-3 is implicated in the regulation of endoplasmic reticulum
(ER)-associated degradation [76]; thus, it is tempting to speculate
that stimulating the aggregation of ataxin-3 might exacerbate ER
stress-related dysfunction. In total, our findings support the general
notion that polyglutamine aggregate-formation contributes to
neurodegeneration by sensitizing cells to physiologic or environ-
mental stress. In this regard, blocking or slowing aggregation elicits
a strong cytoprotective effect in our study. These implications may
hold importance for other protein misfolding diseases such as
Amyotrophic Lateral Sclerosis (ALS), tauopathies, and Parkin-
son’s, Alzheimer’s, and prion disorders.
Materials and Methods
Expression plasmids
cDNA encoding scFv-6E (GenBank accession number
FJ695518) was amplified by PCR using complementary primers
that introduced a 59 Kozak initiation sequence for mammalian
expression and a 39 HA epitope (YPYDVPDYA) for biochemical
detection. The resulting PCR product was ligated downstream of
the strong CMV promoter in pAAV-MCS (Stratagene) using
standard cloning techniques. C4 (GenBank accession number
EU490426) and ML3.9 [46] scFvs were cloned into pAAV-MCS
in a similar manner. To create fluorescently-labeled intrabodies,
humanized enhanced green fluorescent protein (EGFP) was PCR-
amplified (without a start codon) using a complementary forward
primer that introduced an N-terminal (Gly4Ser)4 flexible peptide
repeat. This flexible peptide linker normally mediates proper
folding of VH and VL antibody domains in scFv frameworks but
has been adapted by others to create functional scFv-GFP fusions
[35,36]. PCR-generated (Gly4Ser)4-EGFP fragments were cloned
into the 39 end of the multiple cloning site of pcDNA3.1(-)
(Invitrogen) to accommodate N-terminal fusion with intrabodies.
Next, cDNAs of HA-tagged 6E, ML3.9, and C4 scFvs or untagged
B8 [39] were amplified by PCR (without stop codons) and ligated
upstream of and in-frame to (Gly4Ser)4-EGFP, resulting in the
following orientation: Kozak sequence-intrabody-HA-(Gly4Ser)4-
EGFP-stop. 6E intrabody was tagged with mRFP by replacing
EGFP in the above vector with improved monomeric red-
fluorescent protein (mRFP1 Q66T) [77]. Vectors for the
expression of GFP-labeled human httex1 with different polyglu-
tamine repeat lengths (pcDNA3.1-Httex1-25Q-EGFP,
pcDNA3.1-Httex1-72Q-EGFP) were described elsewhere [78].
Httex1 was labeled with mRFP by replacing EGFP in the above
vectors with mRFP1 (Q66T) [77] using standard cloning
techniques. Likewise, mRFP (Q66T) was N-terminally tagged
with an SV40 NLS (MTPPKKKRKV) using PCR primers and
ligated into pcDNA3.1(-) (Invitrogen) to create NLS-mRFP1.
Through a similar manner, SV40 NLS (TPPKKKRKV) was
cloned onto the C-terminus of scFv-6E or scFv-C4 in pAAV-MCS
(Stratagene) to target these intrabodies into nuclei. Vectors for the
expression of GFP-labeled full-length human ataxin-3 with
different polyglutamine repeat lengths (pEGFP-C1-Ataxin3-24Q;
pEGFP-C1-Ataxin3-Q77) were described elsewhere [24]. A
version of ataxin-3 lacking its polyglutamine domain [7] was
PCR-amplified from pQE30-Ataxin-3 (QHQ) and subcloned into
pEGFP-C1 (Clontech) using standard cloning techniques. All
expression plasmids were confirmed by DNA sequencing.
Cell culture and transfection
Undifferentiated ST14A cells derived from embryonic day 14
rat striatal primordia were propagated at 33uC essentially as
described [27]. Endotoxin-free plasmid DNA was prepared using
EndoFree Plasmid Maxi (Qiagen) and transiently transfected into
ST14A cells using jetPEI DNA transfection reagent (Polyplus-
transfection Inc.) at an N/P ratio of 8. Total amounts of
transfected plasmid were reduced to 60% of the manufacturer’s
recommended amount and culture medium was replaced
,3 hours post-transfection to minimize cellular toxicity. For all
transfections, intrabody plasmids were applied at equal (1:1) or
lesser ratios to httex1 and ataxin-3 plasmids, and cells were
analyzed 48 hours post-transfection.
Cell-free protein aggregation assays
6E and a-PLB scFv antibodies were purified over protein A-
Sepharose as previously described [22]. Recombinant httex1-51Q
protein fused to glutathione S-transferase (GST-Httex1-51Q) was
purified from E. coli and trypsinized to remove GST and initiate
aggregation as described [79]. Surface height analyses of mature
httex1-51Q fibrils were conducted similar to described [40].
Briefly, mature httex1-51Q fibrils were deposited on freshly
cleaved mica and incubated at room temperature for 10 minutes.
Fibril-coated mica were rinsed three times with distilled water and
dried under a gentle stream of N2 gas. For scFv binding, purified
6E or a-PLB scFvs were incubated on fibril-coated mica for an
additional 10 minutes followed by copious rinsing and drying
under N2 gas. Fibril height measurements were performed at three
different sections of mica using Scanning Probe Imaging Processor
(SPIP) software (Image Metrology). Approximately 10 to 20 cross-
sectional surface heights were measured per fibril using line
profiles drawn perpendicular to the fibril axis. Absolute maximum
Z-heights were recorded from each line profile and averaged
among each sample.
For in vitro kinetic aggregation experiments, purified httex1-
51Q was incubated at 37uC with either buffer or scFv-6E at
equimolar ratios in triplicate. Samples were collected and analyzed
at 0, 1, 3, and 24 hours after mixing. Fibril-formation was
quantified using a 25 mM solution of Thioflavine S (Sigma) in PBS
(pH 7.4). 25 mL aliquots of each aggregation reaction (with or
without scFv-6E) were added to 2 mL of ThS solution, and
fluorescence intensity was measured on a Shimadzu RF-5301
spectrofluorophotometer (430 nm excitation, 510 nm emission).
The background fluorescence of ThS alone was subtracted from
each measurement, and triplicate data were averaged. In parallel,
10 mL sample aliquots were deposited on cleaved mica and
imaged by AFM similar to described [21]. Topographic images
were recorded at a resolution of 512 samples per line.
For dot-blot analysis of scFv-6E specificity, freeze-dried GST-
httex1-53Q protein was dissolved in pH 8.0 Tris solution
containing 150 mM NaCl, 0.1 mM EDTA, and 2% glycerol,
and subjected to ultracentrifugation (50,000 g618 hours, 4uC) to
remove any preformed particles. Pre-cleared GST-httex1-53Q
protein (0.1 mg/ml) was digested with PreScission Protease (GE
Healthcare) to remove GST and initiate aggregation. Aliquots of
httex1-53Q were incubated at room temperature and 2.5 mg total
protein was deposited onto nitrocellulose at 0, 1, 6, 24, and
144 hours after initiating aggregation. Dot-blots were air-dried
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labeled with anti-myc and HRP-conjugated anti-mouse antibodies
to immunoprobe scFv-6E, and developed using DAB colorimetric
methods. Staining intensities from duplicate experiments were
quantified and normalized using ImageJ software (http://rsb.info.
nih.gov/ij/).
Cell fractionation and Western blot
Transiently transfected ST14A cells were collected from 6-well
culture dishes by trypsinization and washed twice with PBS.
Whole-cell lysates were extracted at 4uCi n5 0mL/well of RIPA
lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP40,
0.25% sodium deoxycholate, 0.1% SDS) supplemented with 16
Complete protease inhibitor cocktail (Roche). Detergent-insoluble
material was pelleted by microcentrifugation (13,000 rpm610 mi-
nutes, 4uC). Soluble protein in the supernatant was quantified
using Bio-Rad DC Protein Assay kit (Bio-Rad Laboratories).
Lysates were adjusted to 2 mg/mLi n2 6denaturing sample buffer
(125 mM Tris, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol,
0.02% bromophenol blue, pH 6.8) and boiled. Insoluble pellet
fractions were washed with RIPA, resuspended in 50 mL/well of
26 denaturing sample buffer, and boiled for 15 minutes. Equal
volumes of pellet and soluble fractions corresponding to ,20 mgo f
total protein (10 mL) were resolved by SDS-PAGE and transferred
onto PVDF membranes (PerkinElmer). HA-tagged intrabodies
and endogenous actin were probed with monoclonal a-HA
(1:1000, Covance) and a-actin (1:1000, Sigma) Abs, respectively,
labeled with HRP-conjugated goat-anti-mouse Ab (1:2000, Santa
Cruz), and detected by ECL (PerkinElmer).
Live-cell imaging and aggregation counts
ST14A cells transfected with GFP- and/or mRFP-tagged
reporters were imaged directly in 6-well culture dishes using an
OlympusIX70inverted microscopeequipped with anOlympusIX-
FLA Inverted Reflected Light Fluorescence Observation attach-
ment and RGB Mirror Cube filter wheel (Olympus). To maximize
detection of the fluorescent signal, culture medium was replaced
with sterile PBS immediately prior to imaging, and cells were
observed without fixation using a 406lens. Images were captured
48 hours post-transfection with a SPOT RT Color CCD camera
using SPOT Advanced software (Diagnostic Instruments). Camera
exposure times were reduced when imaging protein aggregates due
to their intense fluorescence. Digital images were overlayed and
cropped using Adobe Photoshop. GFP-labeled httex1 or ataxin-3
aggregates were scored in live ST14A cells by counting the number
of visual fluorescent aggregatesfrom 5 separate 206-objective fields,
each showing high percentages of transfected cells, in a single well.
The summations of these counts (number of observed aggregates
per well) were averaged among several independent transfections,
and data were normalized to ST14A cells expressing httex1-72Q-
GFP or GFP-ataxin-3-24Q without intrabody, respectively.
Flow cytometry and toxicity assays
ST14A cells were seeded into 6-well culture dishes (2610
5 cells/
well) and transfected ,24 hours later, in triplicate wells, with
plasmids encoding GFP- or mRFP-tagged httex1 (containing either
normal or expanded polyglutamine repeat tracts) and either
intrabody or empty vector. Approximately 48 hours post-transfec-
tion, cell medium was harvested and adherent cells were collected
bytrypsinization (typically6–8610
5 totalcells/well).Harvested cells
and exhausted media were combined and passed through a 70 mm
cell strainer (BD Biosciences). Cells were pelleted by centrifugation
(4,000 rpm65 minutes) and resuspended in 1 mL of FACS buffer
(16 Ca
2+-a n dM g
2+-free PBS, 10% FBS) containing 50 mM
propidium iodide (Sigma) or 0.5 mM YOPRO-1 (Invitrogen). Cells
were stained for 20 minutes in the dark and pelleted by
centrifugation (4,000 rpm65 minutes). Cell pellets were resus-
pended in 0.5 mL of FACS buffer/well (,10
6 cells/mL) and
transferred to 12675 mm Falcon 5 mL round-bottom polystyrene
FACS tubes. Labeled cells were sorted by fluorescence using a BD
FACSCalibur Flow Cytometer (BD Biosciences) and a minimum of
30,000 events were recorded per sample using BD CellQuest Pro
software. GFP and YOPRO-1 were detected with an FL1 detector,
mRFP with FL2, and propidium iodide with FL3. Prior to each
experiment, the flow cytometer was calibrated against three control
groups: (1) unstained ST14A cells to gate autofluorescence, (2)
unstained ST14A cells expressing GFP- or mRFP-tagged httex1-
25Q alone to identify transfected cells, and (3) stained ST14A cells
pre-treated with H2O2 for maximal PI or YOPRO-1 uptake. Using
BD CellQuest Pro software, data were displayed in two-color dot-
plot formats on a log-scale, and cell death was expressed as a
percentage by dividing the number of transfected cells that stained
with PI or YOPRO-1 in the upper right quadrant by the total
number of transfected cells (summation of the upper and lower right
quadrants). Cell death percentages were normalized to that of
ST14A cells expressing non-expanded httex1-25Q. Toxicity of full-
length ataxin-3 (containing either normal or expanded polygluta-
mine) was determined in a similar manner by FACS.
For analyzing the aggregation of httex1-72Q-GFP by FACS, an
analogous protocol was employed, except that filtered cells were
resuspended in FACS buffer lacking PI or YOPRO-1 and sorted
on the basis of GFP intensity after calibrating against untrans-
fected ST14A cells.
For measuring oxidative stress, filtered cells were resuspended in
16Ca
2+- and Mg
2+-free PBS containing 10 mM dihydroethidium
(Sigma) from a fresh stock in DMSO. Cells were stained for
20 minutes in the dark, washed with 16 Ca
2+- and Mg
2+-free
PBS, and immediately analyzed by flow cytometry after
calibrating against (1) unstained ST14A cells, (2) ST14A cells
expressing non-expanded httex1-25Q-GFP or GFP-ataxin-3-24Q,
and (3) DHE-stained ST14A cells to exclude steady-state oxidation
levels. Ethidium bromide fluorescence was detected with an FL3
detector, and the normalized percentage of transfected cells that
oxidized DHE above background was calculated similar to above.
Statistical analysis
All values represent the mean of at least three independent
experiments (6SEM). Statistical significance was determined by
one-way ANOVA using Minitab or Statview statistical software. P
values,0.05 were designated as statistically significant.
Supporting Information
Figure S1 scFv-C4 fluorobody potently blocks mutant httex1
aggregation and co-localizes perfectly with soluble httex1 in live
cells. ST14A cells were transiently transfected with GFP-tagged
scFv-C4 fluorobody and/or mRFP-tagged httex1-72Q, and
representative live-cell images were captured 48 hours post-
transfection as described in Materials and Methods. In the
absence of intrabody, httex1-72Q-mRFP rapidly forms cytoplas-
mic aggregates. Upon co-transfection with scFv-C4 fluorobody,
aggregation of httex1-72Q-mRFP is potently inhibited, and scFv-
C4 fluorobody co-localizes perfectly with soluble httex1 in the
cytoplasm. In contrast, scFv-C4 fluorobody localizes to the
nucleoplasm and cytoplasm in the absence of httex1 substrate.
Neither GFP-tagged fluorobody nor mRFP-tagged httex1-72Q
was detected outside of expected spectra.
Found at: doi:10.1371/journal.pone.0005727.s001 (6.25 MB TIF)
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